Sign in
Taking people in United StatesPhase 3

Long-term aleniglipron pill study for weight management in adults with obesity

Tests a daily aleniglipron pill against placebo in adults with obesity or overweight.

Key facts

Who runs it
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Where
Albany, Ann Arbor, Austin, Baton Rouge, Birmingham, Brooklyn, Buford, Butte, Charlotte, Chesterfield, Chicago, Clearwater, Columbus, Denison, Durham, Escondido, Fayetteville, Gardena, Greer, Gulfport, Hazelwood, Honolulu, Houston, Iowa City, Knoxville, La Jolla, Las Vegas, Lawrenceville, Leesburg, Louisville, Mankato, Meridian, Methuen, Miami, Missoula, Modesto, Moore, Needham, New Bern, Ocala, Ocoee, Omaha, Pembroke, Philadelphia, Phoenix, Portland, Renton, Rexburg, Richfield, Ridgeland, Rolling Hills Estates, San Antonio, San Diego, Sandy City, Silver Spring, St Louis, St. George, Sun City West, Tampa, Tucson, Union City, Wichita, Wilmington, Winston-Salem, Woodstock, and Wylie, United StatesSee the 66 sites
Trial code
Registry title
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Status
Recruiting
Phase
Phase 3
People taking part
3,600 people, planned
Started
13 Jul 2026
Expected to end
Nov 2028
Type of study
Interventional, 4 groups
Treatments tested
  • Aleniglipron
  • Placebo
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, or with overweight and a weight-related health problem. It tests the pill aleniglipron against placebo for weight loss.

Age
18 to 79 years
Sex
Men and women can join.
Disease stage
BMI of 30 kg/m2 or more (obesity), or BMI of 27 kg/m2 or more (overweight) with at least 1 weight-related health problem.
Earlier treatment
People who have had, or plan to have, surgery or other treatment for obesity cannot join. This includes endoscopic or device-based treatment.

Main reasons for not taking part

  • Diabetes of any type
  • Body weight change of more than 5 kg (11 lb) in the 3 months before screening
  • Obesity caused by other hormone disorders
  • Weak kidney function at screening
  • Chronic malabsorption

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Signed informed consent
  • BMI ≥30 kg/m2 (obese) or BMI ≥27 kg/m2 (overweight) and presence of ≥1 of the obesity related comorbidities

Who cannot take part

  • Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Self-reported change in body weight >5 kg within 3 months before Screening
  • Have prior or planned surgical or non-surgical treatment for obesity
  • Have or plan to have endoscopic and/or device-based therapy for obesity
  • Have obesity induced by other endocrine disorders
  • Impaired renal function at Screening
  • Chronic malabsorption

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Where in United States

  • Albany, New YorkHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Ann Arbor, MichiganHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Austin, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Baton Rouge, LouisianaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Birmingham, AlabamaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Brooklyn, New YorkHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Buford, GeorgiaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Butte, MontanaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Charlotte, North CarolinaHospital not named in the registryContact: Medical DirectorTaking people
  • Chesterfield, MissouriHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Chicago, IllinoisHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Clearwater, FloridaHospital not named in the registryContact: Medical DirectorTaking people
  • Columbus, GeorgiaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Denison, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Durham, North CarolinaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Escondido, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Fayetteville, North CarolinaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Gardena, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Greer, South CarolinaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Gulfport, MississippiHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Hazelwood, MissouriHospital not named in the registryContact: Medical DirectorTaking people
  • Honolulu, HawaiiHospital not named in the registryContact: Medical DirectorTaking people
  • Houston, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Iowa City, IowaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Knoxville, TennesseeHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • La Jolla, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Las Vegas, NevadaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Lawrenceville, GeorgiaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Leesburg, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Louisville, KentuckyHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Mankato, MinnesotaHospital not named in the registryContact: Medical DirectorTaking people
  • Meridian, IdahoHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Methuen, MassachusettsHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Miami, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Missoula, MontanaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Modesto, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Moore, OklahomaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Needham, MassachusettsHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • New Bern, North CarolinaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Ocala, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Ocoee, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Omaha, NebraskaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Pembroke, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Philadelphia, PennsylvaniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Phoenix, ArizonaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Portland, OregonHospital not named in the registryContact: Medical DirectorTaking people
  • Renton, WashingtonHospital not named in the registryContact: Medical DirectorTaking people
  • Rexburg, IdahoHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Richfield, MinnesotaHospital not named in the registryContact: Medical DirectorTaking people
  • Ridgeland, MississippiHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Rolling Hills Estates, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • San Antonio, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • San Diego, CaliforniaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Sandy City, UtahHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Silver Spring, MarylandHospital not named in the registryContact: Medical DirectorTaking people
  • St Louis, MissouriHospital not named in the registryContact: Medical DirectorTaking people
  • St. George, UtahHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Sun City West, ArizonaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Tampa, FloridaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Tucson, ArizonaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Union City, GeorgiaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Wichita, KansasHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Wilmington, North CarolinaHospital not named in the registryContact: Medical DirectorTaking people
  • Winston-Salem, North CarolinaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Woodstock, GeorgiaHospital not named in the registryContact: Medical DirectorNot yet recruiting
  • Wylie, TexasHospital not named in the registryContact: Medical DirectorNot yet recruiting

About the trial

What the trial wants to find out

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.

The 4 groups in the trial

  • aleniglipron Arm 1Treatment being tested

    Participants will receive aleniglipron administered orally.

    Treatment: Aleniglipron

  • aleniglipron Arm 2Treatment being tested

    Participants will receive aleniglipron administered orally.

    Treatment: Aleniglipron

  • aleniglipron Arm 3Treatment being tested

    Participants will receive aleniglipron administered orally.

    Treatment: Aleniglipron

  • Placebo Arm 4Treatment being tested

    Participants will receive placebo administered orally.

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity
Plain-language title
Long-term aleniglipron pill study for weight management in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07654361, who can take part
Record updated
10 August 2026